Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

Christine H. Chung, Erin H. Seeley, Heinrich Roder, Julia Grigorieva, Maxim Tsypin, Joanna Roder, Barbara A. Burtness, Athanassios Argiris, Arlene A. Forastiere, Jill Gilbert, Barbara Murphy, Richard M. Caprioli, David P. Carbone, Ezra E.W. Cohen

Resultado de la investigación: Articlerevisión exhaustiva

47 Citas (Scopus)


Background: We hypothesized that a serum proteomic profile predictive of survival benefit in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) reflects tumor EGFR dependency regardless of site of origin or class of therapeutic agent. Methods: Pretreatment serum or plasma from 230 patients treated with cetuximab, EGFR-TKIs, or chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) were analyzed by mass spectrometry. Each sample was classified into "good" or "poor" groups using Veri Strat, and survival analyses of each cohort were done based on this classification. For the CRC cohort, this classification was correlated with the tumor EGFR ligand levels and KRAS mutation status. Results: In the EGFR inhibitor-treated cohorts, the classification predicted survival (HNSCC: gefitinib, P = 0.007 and erlotinib/bevacizumab, P = 0.02; CRC: cetuximab, P = 0.0065) whereas the chemotherapy cohort showed no survival difference. For CRC patients, tumor EGFR ligand RNA levels were significantly associated with the proteomic classification, and combined KRAS and proteomic classification provided improved survival classification. Conclusions: Serum proteomic profiling can detect clinically significant tumor dependence on the EGFR pathway in non-small cell lung cancer, HNSCC, and CRC patients treated with either EGFR-TKIs or cetuximab. This classification is correlated with tumor EGFR ligand levels and provides a clinically practical way to identify patients with diverse cancer types most likely to benefit from EGFR inhibitors. Prospective studies are necessary to confirm these findings.

Idioma originalEnglish (US)
Páginas (desde-hasta)358-365
Número de páginas8
PublicaciónCancer Epidemiology Biomarkers and Prevention
EstadoPublished - feb 2010
Publicado de forma externa

ASJC Scopus subject areas

  • Epidemiology
  • Oncology


Profundice en los temas de investigación de 'Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients'. En conjunto forman una huella única.

Citar esto